Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 47

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 47
---
 ​ |     ​ | ​ | ​ | ​ | 1,386,700 | ​ |         ​ |   |   |
| Brett A. Grimaud﻿(6)Senior Vice President, General Counsel & Secretary | ​ | ​ |    ​ | ​ | 2024 | ​ | ​ | ​ |            ​ | ​ |   480,870 | ​ | ​ | ​ |           ​ | ​ |     — | ​ | ​ | ​ |                 ​ | ​ |   790,624 | ​ | ​ | ​ |                                         ​ | ​ | 205,000 | ​ | ​ | ​ |                           ​ | ​ | 5,000 | ​ | ​ | ​ |         ​ | ​ | 1,481,494 | ​ | ​ |

(1) Includes amounts deferred pursuant to our 401(k) plan. (2) Reflects a cash bonus awarded to Mr. Winningham at the discretion of the compensation committee, as discussed in greater detail in the “2024 Base Salaries and Annual Incentive Opportunities” section of the “Narrative Disclosure to Summary Compensation Table” beginning on page 31. (3) The amounts in these columns reflect the aggregate grant date fair value of share awards and option awards granted by us, computed in accordance with FASB ASC Topic 718. See Notes 1 and 12 of the notes to our consolidated financial statements in our Annual Report on Form 10-K filed on March 7, 2025 for a discussion of all assumptions made by us in determining the grant date fair value of such awards. In accordance with SEC rules, the grant date fair value of any award subject to a performance condition is based on the probable outcome of the performance conditions. Messrs. Winningham, Sawaf and Grimaud were each granted performance-contingent RSUs in April 2024, the vesting of which are tied to the achievement of performance milestones, as described in greater detail in the “2024 Equity Compensation” section of the “Narrative Disclosure to Summary Compensation Table” beginning on page 34. The performance-contingent RSUs granted to Messrs. Winningham, Sawaf and Grimaud in April 2024 are market-based awards, and the grant date fair value was determined using a Monte-Carlo valuation method. The grant date fair value for the performance-contingent RSUs included in the “share awards” column for each of the named executive officers is as follows: Mr. Winningham